新版　新生児内分泌ハンドブック

出版社： メディカ出版
著者：
発行日： 2020-06-15
分野： 臨床医学：内科  >  周産期(新生児)
ISBN： 9784840472289
電子書籍版： 2020-06-15 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

新たに、早産児骨減少症、緊急対応が必要な先天代謝異常症、循環作動薬などの項目を追加。新生児疾患に深く関与することが明らかになった内分泌は、呼吸、循環、神経、栄養に続き、新生児の第５のテーマといえる。新生児内分泌の基礎から応用が学べ、新生児管理の臨床で生かせるように、第一人者が最新知識を臨床上の着眼点とともに解説する。

目次

  • 【総 論】
    〔1〕胎児期の内分泌系の発達からみた「新生児内分泌」の重要性
    〔2〕乳幼児期の内分泌機能の発達
    〔3〕新生児・乳幼児・小児の内分泌に関する検査の注意点

    【各 論】
    〔1〕下垂体
    〔2〕副腎皮質
    〔3〕甲状腺
    〔4〕糖代謝
    〔5〕電解質・カルシウム代謝
    〔6〕性腺
    〔7〕代謝
    〔8〕母体合併症
    〔9〕ステロイド療法
    〔10〕新生児内分泌と循環
    〔11〕NICU退院児の成長における内分泌学的問題点

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.9 掲載の参考文献
1) Godfrey, KM. et al. Fetal nutrition and adult disease. Am J Clin Nutr, 71 (5 suppl), 2000, 1344S-52S.
 
2) 日本小児内分泌学会成長ホルモン委員会・日本未熟児新生児学会薬事委員会. SGA性低身長症に対するGH療法のガイドライン. 日本小児科学会雑誌. 111 (4), 2007, 641-6.
 
3) Hashimoto, Y. et al. Fetal growth restriction but not preterm birth is a risk factor for severe hypospadias. Pediatr Int. 58 (7), 2016, 573-7.
 
4) Sir-Petermann, T. et al. Gonadal function in low birth weight infants : a pilot study. J Pediatr Endocrinol Metab. 20 (3), 2007, 405-14.
PubMed
5) Garland, JS. et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates : a randomized trial. Pediatrics. 104 (1 Pt 1), 1999, 91-9.
 
6) Watterberg, KL. et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia : a multicenter trial. Pediatrics. 114 (6), 2004, 1649-57.
PubMed
7) Barrington, KJ. et al. The adverse neuro-developmental effects of postnatal steroids in the preterm infant : a systematic review of RCTs. BMC Pediatrics. 1 (1), 2001. [Epub]
 
8) Watterberg, KL. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 126 (4), 2010, 800-8.
PubMed
9) Kawai, M. Late onset circulatory collapse of prematurity. Pediatr Int. 59 (4), 2017, 391-6.
PubMed
10) Narumi, S. et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 48 (7), 2016, 792-7.
 
11) van Wassenaer, AG. et al. Thyroid function in very preterm infants : influences of gestational age and disease. Pediatr Res. 42 (5), 1997, 604-9.
PubMed
12) Osborn, DA. et al. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia. Cochrane Database Syst Rev. 1, 2007, CD005945.
PubMed
13) Kawai, M. et al. National wide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birth-weight infants in Japan. Pediatr Int. 54 (2), 2012, 177-81.
 
14) 日本小児内分泌学会マス・スクーリング委員会, 日本マス・スクリーニング学会. 先天性甲状腺機能低下症マス・スクリーニングガイドライン (2014年改訂版). 2014. http://jspe.umin.jp/medical/files/CH_gui.pdf (2020年3月閲覧)
 
15) 河井昌彦. "Basedow病母体児". 新生児医学. 京都, 金芳堂, 2015, 387-8.
 
16) Stanley, CA. et al. Re-evaluating "transitional neonatal hypoglycemia" : mechanism and implications for management. J Pediatr. 166 (6), 2015, 1520-5.
PubMed
17) Stanley, CA. Hypoglycemia in the neonate. Pediatr Endocrinol Rev. 4 (suppl 1), 2006, 76-81.
 
18) 河井昌彦. "新生児期の下垂体機能不全症を疑う主要症候". イラストで見る診る学ぶ新生児内分泌. 大阪, メディカ出版, 2011, 159-60.
 
19) Nagai, S. et al. Gonadotropin Levels in Urine during Early Postnatal Period in Small for Gestational Age Preterm Male Infants with Fetal Growth Restriction. J Perinatol. 37 (7), 2017, 843-7.
PubMed
20) Hughson, M. et al. Glomerular number and size in autopsy kidneys : the relationship to birth weight. Kidney Int. 63 (6), 2003, 2113-22.
PubMed
21) Ng, Pak C. et al. A prospective longitudinal study to estimate the "adjusted cortisol percentile" in preterm infants. Pediatr Res. 69 (6), 2011, 511-6.
PubMed
22) 河井昌彦. "胎児～早産児のステロイド産生". 周産期・新生児ステロイドを使いこなそう!. 京都, 金芳堂, 2018, 18-37.
 
P.19 掲載の参考文献
1) 神崎晋. "成長の機構とその制御". 小児内分泌学. 日本小児内分泌学会編. 東京. 診断と治療社. 2016, 171-7.
 
2) Karlberg, JA. Biologically-oriented mathematical model (ICP) for human growth. Acta Pediatr Scand. Suppl. 350, 1989, 70-94.
 
3) Styne, DM. et al. "Physiology and disorders of puberty". Williams Textbook of Endocrinology. Melmed, S. et al. ed. Philadelphia, Elsevier, 2016, 1074-218.
 
4) Yakar, S. et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U. S. A. 96 (13), 1999, 7324-9.
PubMed
5) Ohlsson, C. et al. Growth hormone and bone. Endcr Rev. 19 (1), 1998, 55-79.
 
6) Cooke, DW. et al. "Normal and aberrant growth in children". Williams Textbook of Endocrinology. Melmed, S. et al. ed. Philadelphia, Elsevier, 2016, 964-1073.
 
7) Binder, G. et al. Rational approach to the diagnosis of severe growth hormone deficiency in the newborn. J Clin Endocrinol Metab. 95 (5), 2010, 2219-26.
 
8) Vliet, GV. et al. "Disorders of the thyroid in the newborn and infant". Pediatric Endocrinology. Sperling, MA. ed. Philadelphia, Elsevier, 2014, 187-209.
 
9) Kawahara, K. et al. Establishment of reference intervals of thyrotropin and free thyroid hormones during the first week of life. Clin Pediatr Endocrinol. 11 (1), 2002, 1-9.
 
10) Verburg, FA. et al. Reference ranges for analytes of thyroid function in children. Horm Metab Res. 43 (6), 2011, 422-6.
PubMed
11) 立花克彦. "内分泌学的検査". 日本人基準値の臨床検査基準値. 日本基準値研究班編. 日本公衆衛生協会. 1997, 375-94.
 
12) Kuiri-Hanninen, T. et al. Activation of the hypothlamic-pituitary-gonadal axis in infancy : minipuberty. Horm Res Pediatr. 82 (2), 2014, 73-80.
 
13) Bergada, I. et al. Time course of the serum gonadotropin surge, inhibins, and anti-mullerian hormone in normal newborn males during the first month of life. J Clin Endocrinol Metab. 91 (10), 2006, 4092-8.
 
14) Lamminmaki, A. et al. Testosterone measured in infancy predicts subsequent sex-typed behavior in boys and in girls. Horm Behav. 61, 2012, 611-6.
PubMed
15) Bay, K. et al. Insulin-like factor 3 levels in cord blood and serum from children : effects of age, postnatal hypothalamic-pituitary-gonadal axis activation, and cryptorchidism. J Clin Endocrinol Metab. 92 (10), 2007, 4020-7.
PubMed
16) Aksglaede, L. et al. Changes in anti-mullerian hormone (AMH) throughout the life span : a population-based study of 1,027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endcrinol Metab. 95 (12), 2010, 5357-64.
 
17) Kuiri-Hanninen, T. et al. Increased activity of the hypothalamic-pituitary-testicular axis in infancy results in increased androgen action in premature boys. J Clin Endocrinol Metab. 96 (1), 2011, 98-105.
 
18) Chemes, HE. et al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in sertoli cells. J Clin Endocrinol Metab. 93 (11), 2008, 4408-12.
PubMed
19) Price, DA. et al. Age of appearance of circadian rhythm in salivary cortisol values in infancy. Arch Dis Child. 58, 1983, 454-6.
PubMed
20) Santiago, LB. et al. Longitudinal evaluation of the development of salivary cortisol circadian rhythm in infancy. Clin Endocrinol. 44 (2), 1996, 157-61.
PubMed
21) Custodio, RJ. et al. The emergence of the cortisol circadian rhythm in monozygotic and dizygotic twin infants : the twin-pair synchrony. Clin Endocrinol. 66 (2), 2007, 192-7.
PubMed
22) Seron-Ferre, M. et al. Twenty-four-hour pattern of cortisol in the human fetus at term. Am J Obstet Gynecol. 184 (6), 2001, 1278-83.
PubMed
23) Iwata, O. et al. Diurnal cortisol changes in newborn infants suggesting entrainment of peripheral circadian clock in utero and at birth. J Clin Endocrinol Metab. 98 (1), 2013, E25-E32.
 
24) Martinerie, L. et al. Physiological partial aldosterone resistance in human newborns. Pediatr Res. 66 (3), 2009, 323-8.
PubMed
25) Martinerie, L. et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology. 150 (9), 2009, 4414-24.
PubMed
P.27 掲載の参考文献
1) 河井昌彦. 血糖測定. 小児内科. 51, 2019, 717-9.
Medical*Online
2) 河井昌彦. "ケトン性低血糖症とは?". イラストで見る診る学ぶ新生児の栄養・代謝. 大阪, メディカ出版, 2013, 132-3.
 
3) 愛知県臨床検査標準化協議会. 臨床化学検査の手引書-分析前段階-. 平成22年3月. http://www.aichi-amt.or.jp/hyojunka/pdf/hyojunka/guide-8.pdf#search='溶血と検査値' (2020年1月閲覧)
 
4) 濱崎直孝ほか. 臨床検査の正しい仕方-検体採取から測定まで-. 東京, 宇宙堂八木書店, 2008, 120p.
 
5) Fisher, DA. Thyroid function in premature infants. Clinics in Perinatology. 25 (4), 1998, 999-1014.
PubMed
6) 日本小児内分泌学会マス・スクリーニング委員会, 日本マス・スクリーニング学会. 先天性甲状腺機能低下症マス・スクリーニングガイドライン (2014年改訂版). http://jspe.umin.jp/medical/files/CH_gui.pdf (2020年1月閲覧)
 
7) 香美祥二. 腎臓レニン・アンジオテンシン系 (RAS) : 生命の環を支え, 脅かすもの. 日本小児腎臓病学会雑誌. 26 (2), 2014, 227-31.
 
8) Sulyok, E. et al. Relationship between Maturity, Electrolyte Balance and the Function of the Renin-Angiotensin-Aldosterone System in Newborn Infants. Biol Neonate. 35 (1-2), 1979, 60-5.
PubMed
9) Martinerie, L. et al. Physiological partial aldosterone resistance in human newborns. Pediatr Res. 66 (3), 2009, 323-8.
PubMed
10) Binder, G. et al. Rational approach to the diagnosis of severe growth hormone deficiency in the newborn. J Clin Endocrinol Metab. 95 (5), 2010, 2219-26.
 
11) 河井昌彦. アンモニア測定の注意点. イラストで見る診る学ぶ新生児の栄養・代謝. 大阪, メディカ出版, 2013, 113.
 
12) Burton, BK. Inherited Metabolic Disorders. Avery's Neonatology-Physiology and management of the newborn. 7th ed. Philadelphia, Lippincott William & Wilkins, 2016.
 
13) Nagai, S. et al. Gonadotropin levels in urine during early postnatal period in small for gestational age preterm male infants with fetal growth restriction. J Perinatol. 37 (7), 2017, 843-7.
PubMed
14) エクルーシス(R) 試薬テストステロン II. 添付資料. 2011年6月改訂 (第3版). https://www.kuhp.kyoto-u.ac.jp/~kensa/reference/item/pdf/1165attachment.pdf (2020年1月閲覧)
 
15) Tahara, Y. et al. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 18, 1995, 440-7.
PubMed

各論

P.43 掲載の参考文献
1) Bancalari, RE. et al. Pituitary gland development : an update. Endocr Dev. 23, 2012, 1-15.
PubMed
2) 笠井貴敏ほか. 下垂体の立体組織構築. 医学のあゆみ. 264 (8), 2018, 653-8.
Medical*Online
3) Suga, H. Application of pluripotent stem cells for treatment of human neuroendocrine disorders. Cell Tissue Res. 375 (1), 2019, 267-78.
PubMed
4) 楠田聡. 新生児内分泌機能の出生後の適応. 周産期医学. 48 (11), 2018, 1450-6.
Medical*Online
5) Kawai, M. Late-onset circulatory collapse of prematurity. Pediatr Int. 59 (4), 2017, 391-6.
PubMed
6) 大沼真輔ほか. 性腺疾患におけるトランジション : 小児科の立場から. 最新医学. 74 (5), 2019, 653-9.
Medical*Online
7) Lanciotti, L. et al. Up-To-Date Review About Minipuberty and Overview on Hypothalamic-Pituitary-Gonadal Axis Activation in Fetal and Neonatal Life. Front Endocrinol (Lausanne). 9, 2018, 410.
PubMed
8) Hawkes, CP. et al. The relationship between IGF-I and -II concentrations and body composition at birth and over the first 2 months. Pediatr Res. 85 (5), 2019, 687-92.
PubMed
9) 沼倉周彦. 下垂体機能異常症が疑われるとき. 小児科診療. 74 (suppl), 2011, 370-5.
Medical*Online
10) Castinetti, F. et al. MECHANISMS IN ENDOCRINOLOGY : An update in the genetic aetiologies of combined pituitary hormone deficiency. Eur J Endocrinol. 174 (6), 2016, R239-47.
 
11) Couture, C. et al. Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTH-deficiency patients with TPIT gene mutations. J Clin Endocrinol Metab. 97 (3), 2012, E486-95.
 
12) Fukuoka, T. et al. Total Bile acid concentration in duodenal fluid is a useful preoperative screening marker to rule out biliary atresia. J Pediatr Gastroenterol Nutr. 67 (3), 2018, 383-7.
PubMed
13) 三善陽子. "全身疾患による肝病変 : 内分泌異常と肝障害". 小児栄養消化器肝臓病学. 日本小児栄養消化器肝臓学会編. 東京, 診断と治療社, 2014, 463-4.
 
14) Ishii, T. et al. A cross-sectional growth reference and chart of stretched penile length for Japanese boys aged 0-7 years. Horm Res Paediatr. 82 (6), 2014, 388-93.
 
15) 朝倉由美. 下垂体機能低下症. 小児科診療. 81 (suppl), 2018, 582-5.
Medical*Online
16) Cemeroglu, AP. et al. Spectrum of clinical presentations and endocrinological findings of patients with septo-optic dysplasia : a retrospective study. J Pediatr Endocrinol Metab. 28 (9-10), 2015, 1057-63.
 
17) Koizumi, M. et al. Endocrine status of patients with septo-optic dysplasia : fourteen Japanese cases. Clin Pediatr Endocrinol. 26 (2), 2017, 89-98.
PubMed
18) Ucar, A. et al. Diagnosis and management of pediatric adrenal insufficiency. World J Pediatr. 12 (3), 2016, 261-74.
PubMed
19) Zwaveling-Soonawala, N. et al. TSH and FT4 concentrations in congenital central hypothyroidism and mild congenital thyroidal hypothyroidism. J Clin Endocrinol Metab. 103 (4), 2018, 1342-8.
PubMed
20) Nebesio, TD. et al. Newborn screening results in children with central hypothyroidism. J. Pediatr. 156 (6), 2010, 990-3.
PubMed
21) Boehm, U. et al. Expert consensus document : European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 11 (9), 2015, 547-64.
PubMed
22) Binder, G. et al. Rational approach to the diagnosis of severe growth hormone deficiency in the newborn. J Clin Endocrinol Metab. 95 (5), 2010, 2219-26.
 
23) Cox, TD. et al. Normal pituitary gland : changes in shape, size, and signal intensity during the 1st year of life at MR imaging. Radiology. 179 (3), 1991, 721-4.
PubMed
24) Higuchi, A. et al. Dose Adjustments of Hydrocortisone and L-thyroxine in Hypopituitarism Associated with Cholestasis. Clin Pediatr Endocrinol. 15 (3), 2006, 93-6.
PubMed
25) 室谷浩二. "低ゴナドトロピン性性腺機能低下症 : Kallmann症候群以外の先天性低ゴナドトロピン性性腺機能低下症". 小児内分泌学. 改訂第2版. 日本小児内分泌学会編. 東京, 診断と治療社, 2016, 304-9.
 
P.53 掲載の参考文献
1) Goto, M. et al. Pituitary-adrenal axis during human development. Clin Podiatry Endocrinol. 16 (2), 2007, 37-44.
 
2) 長谷川奉延ほか. "新生児副腎皮質機能の評価方法". 改訂2版 新生児内分泌ハンドブック. 新生児内分泌研究会編. 大阪, メディカ出版, 2014, 33.
 
3) Rainey, WE. et al. Regulation of the adrenal androgen biosynthesis. J Steroid Biochem Mol Biol. 108 (3-5), 2008, 281-6.
 
4) Fowden, AL. et al. Endocrine regulation of feto-placental growth. J Horm Res. 72 (5), 2009, 257-65.
 
5) Xatzipsalti, M. et al. Congenital hypopituitarism : various genes, various phenotypes. Horm Metab Res. 51 (2), 2019, 81-90.
PubMed
6) Menon, K. et al. A randomized controlled trial of corticosteroids in pediatric septic shock : a pilot feasibility study. Pediatr Crit Care Med. 18 (6), 2017, 505-12.
 
7) Kirkgoz, T. et al. Primary adrenal insufficiency in children : diagnosis and management. Best Pract Res Clin Endocrinol Metab. 32 (4), 2018, 397-424.
PubMed
8) Eyal, O. et al. Adrenal crises in children with adrenal insufficiency : epidemiology and risk factors. Eur J Pediatr. 78 (5), 2019, 731-78.
 
9) Koyama, Y. et al. Urinary steroid profiling : a powerful method for the diagnosis of abnormal steroidogenesis. Expert Rev Endocrinol Metab. 9 (3), 2014, 273-82.
PubMed
10) Hamrahian, AH. et al. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 350 (16), 2004, 1629-38.
PubMed
11) Hanna, CE. et al. Corticosteroid binding globulin, total serum cortisol, and stress in extremely low-birth-weight infants. Am J Perinatol. 14 (4), 1997, 201-4.
PubMed
12) Ivars, K. et al. Development of salivary cortisol circadian rhythm in preterm infants. PLoS One. 10 ; 12 (8), 2017, e0182685.
PubMed
13) Heckmann, M. et al. Reference range for serum cortisol in well preterm infants. Arch Dis Child Fetal Neonatal Ed. 81 (3), 1999, F171-4.
PubMed
14) Heckmann, M. et al. Serum cortisol concentrations in ill preterm infants less than 30 weeks gestational age. Acta Paediatr. 89 (9), 2000, 1098-103.
PubMed
15) Ng, PC. et al. A prospective longitudinal study to estimate the "adjusted cortisol percentile" in preterm infants. Pediatr Res. 69 (6), 2011, 511-6.
PubMed
16) Ng, SM. et al. Adrenal function of extremely premature infants in the first 5 days after birth. J Pediatr Endocrinol Metab. 32 (4), 2019, 363-7.
 
17) Mori, A. et al. Plasma cortisol and ACTH levels in 416 VLBW preterm infants during the first month of life : distribution in the AGA/SGA population. J Perinatol. 39 (7), 2019, 934-40.
PubMed
18) 日本内分泌学会. 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌. 91 (Suppl), 2015, 1-78.
 
19) Fernandez, EF. et al. ACTH and cortisol response to critical illness in term and late preterm newborns. J Perinatol. 28 (12), 2008, 797-802.
PubMed
20) Korte, C. et al. Adrenocortical function in the very low birth weight infant : improved testing sensitivity and association with neonatal outcome. J Pediatr. 128 (2), 1996, 257-63.
PubMed
21) Watterberg, KL. et al. Effect of dose on response to adrenocorticotropin in extremely low birth weight infants. J Clin Endocrinol Metab. 90 (12), 2005, 6380-5.
PubMed
22) Baud, O. et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC) : a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 387 (10030), 2016, 1827-36.
PubMed
23) Ng, PC. et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 89 (2), 2004, F119-26.
PubMed
24) Ng, PC. et al. Refractory hypotension in preterm infants with adrenocortical insufficiency. Arch Dis Child Fetal Neonatal Ed. 84 (2), 2001, F122-4.
PubMed
25) Iwanaga, K. et al. Corticotrophin-releasing hormone stimulation tests for the infants with relative adrenal insufficiency. Clin Endocrinol (Oxf). 87 (6), 2017, 660-4.
PubMed
26) Scott, SM. Et al. Effect of gestational age, postnatal age, and illness on plasma cortisol concentrations in premature infants. Pediatr Res. 37 (1), 1995, 112-6.
PubMed
27) Niwa, F. et al. Limited response to CRH stimulation tests at 2 weeks of age in preterm infants born at less than 30 weeks of gestational age. Clin Endocrinol (Oxf). 78 (5), 2013, 724-9.
PubMed
28) Martinerie, L. et al. Physiological partial aldosterone resistance in human newborns. Pediatr Res. 66 (3), 2009, 323-8.
PubMed
29) Martinerie, L. et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology. 150 (9), 2009, 4414-24.
PubMed
30) Martinerie, L. et al. Aldosterone-signaling defect exacerbates sodium wasting in very preterm neonates : the premaldo study. J Clin Endocrinol Metab. 100 (11), 2015, 4074-81.
PubMed
31) Agarwal, S. et al. Fetal adrenal gland biometry and cervical elastography as predictors of preterm birth : a comparative study.Ultrasound. 26 (1), 2018, 54-62.
PubMed
P.65 掲載の参考文献
1) 田島敏広ほか. "先天性副腎過形成症". 小児内分泌学. 改訂第2版. 東京, 診断と治療社, 2016, 371-94.
 
2) 田島敏広ほか. 21-水酸化酵素欠損症の診断・治療のガイドライン (2014年改訂版). 日本小児内分泌学会マス・スクリーニング委員会. http://jspe.umin.jp/medical/files/guide20140513.pdf (2020年2月閲覧)
 
3) 日本小児内分泌学会性分化・副腎疾患委員会. Webtext : 性分化疾患の診断と治療. http://jspe.umin.jp/medical/files/webtext_170104.pdf (2020年2月閲覧)
 
4) Prader, A. Der genitalbefund beim Peseudohermaphriditismus femininus des kongenitalen adrenogenitalen Syndroms. Morphologie, Haufigkeit, Entwicklung und Vererbung der verschiedenen Genitalformen. Helv Paediatr Acta. 9, 1954, 231.
PubMed
5) Homma, K. et al. Elevated urine pregnanetriolone definitively establishes the diagnosis of classical 21-hydroxylase deficiency in term and preterm neonates. J Clin Endocrinol Metab. 89 (12), 2004, 6087-91.
PubMed
6) 尿ステロイドプロフィル検査依頼サイト. 慶應義塾大学病院臨床検査科. https://sites.google.com/keio.jp/steroids/ (2020年2月閲覧)
 
P.75 掲載の参考文献
1) Fluck, CE. MECHANISMS IN ENDOCRINOLOGY : Update on pathogenesis of primary adrenal insufficiency ; beyond steroid enzyme deficiency and autoimmune adrenal destruction. Eur J Endocrinol. 177 (3), 2017, R99-R111.
 
2) Amano, N. et al. Genetic defects in pediatric-onset adrenal insufficiency in Japan. Eur J Endocrinol. 177 (2), 2017, 187-94.
PubMed
3) Baquedano, M. et al. Unique dominant negative mutation in the N-Terminal mitochondrial targeting sequence of StAR, causing a variant form of congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metabolism. 98 (1), 2013, E153-E161.
 
4) El-Khairi, R. et al. Role of DAX-1 (NR0B1) and steroidogenic factor-1 (NR5A1) in human adrenal function. Endocrin Dev. 20, 2010, 38-46.
 
5) Schimmer, BP. & White, PC. Minireview : steroidogenic factor 1 : its roles in differentiation, development, and disease. Mol Endocrinol Baltim Md. 24 (7), 2010, 1322-37.
 
6) Narumi, S. et al. SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet. 48 (7), 2016, 792-7.
 
7) Meimaridou, E. et al. ACTH resistance : genes and mechanisms. Endocrin Dev. 24, 2013, 57-66.
 
8) Meimaridou, E. et al. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet. 44 (7), 2012, 740-2.
PubMed
9) Prasad, R. et al. Thioredoxin reductase 2 (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD). J Clin Endocrinol Metabolism. 99 (8), 2014, E1556-E1563.
 
10) Hughes, CR. et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest. 122 (3), 2012, 814-20.
PubMed
11) Roucher-Boulez, F. et al. NNT mutations : a cause of primary adrenal insufficiency, oxidative stress and extra-adrenal defects. Eur J Endocrinol. 175 (1), 2016, 73-84.
PubMed
12) Jira, P. et al. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Ann Hum Genet. 67, 2003, 269-80.
PubMed
13) Nowaczyk, MJ. & Irons, MB. Smith-Lemli-Opitz syndrome : phenotype, natural history, and epidemiology. Am J Medical Genetics Part C Seminars Medical Genetics. 160C (4), 2012, 250-62.
 
14) Klouwer, FC. et al. Zellweger spectrum disorders : clinical overview and management approach. Orphanet J Rare Dis. 10, 2015, 151.
PubMed
15) Prasad, R. et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest. 127 (3), 2017, 942-53.
PubMed
16) Lovric, S. et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. J Clin Invest. 127 (3), 2017, 912-28.
PubMed
P.87 掲載の参考文献
1) 原田正平. "甲状腺ホルモン : マススクリーニングの問題点". 改訂2版 新生児内分泌ハンドブック. 新生児内分泌研究会編. 大阪, メディカ出版, 2014, 63.
 
2) Mass Screening Committee, Japanese Society for Pediatric Endocrinology, Japanese Society for Mass Screening. Nagasaki, K. et al. Guidelines for Mass Screening of Congenital Hypothyroidism (2014 revision). Clin Pediatr Endocrinol. 24 (3), 2015, 107-33.
PubMed
3) Ohnishi, H. et al. Clinical utility of thyroid ultrasonography in the diagnosis of congenital hypothyroidism. Endocr J. 49, 2002, 293-7.
PubMed
4) Suzuki, S. et al. Systematic determination of thyroid volume by ultrasound examination from infancy to adolescence in Japan : the Fukushima Health Management Survey. Endocr J. 62 (3), 2015, 261-8.
PubMed
5) Leger, J. et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab. 99 (2), 2014, 363-84.
PubMed
6) Rose, SR. et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics. 117 (6), 2006, 2290-303.
PubMed
7) 南谷幹史. 先天性甲状腺機能低下症のマススクリーニングにおける世界の動向・最近の話題と課題. 日本マススクリーニング学会誌. 28 (1), 2018, 53-62.
Medical*Online
8) 田島敏広. 先天性甲状腺機能低下症の新生児マススクリーニング. 日本小児科学会雑誌. 123 (1), 2019, 14-22.
 
9) Ford, G. et al. Screening for congenital hypothyroidism : a worldwide view of strategies. Best Pract Res Clin Endocrinol Metab. 28 (2), 2014, 175-87.
PubMed
10) Uchiyama, A. et al. National survey on concepts for congenital hypothyroidism screening in neonatal intensive care units in Japan. Pediatr Int. 58 (12), 2016, 1311-5.
PubMed
11) 先天性代謝異常等検査実施状況 (平成29年度). 特殊ミルク情報. 54, 2018, 67.
 
12) 柴田奈央ほか. 新生児マススクリーニングTSH高値を呈したDown症候群の頻度と臨床的特徴. 日本マススクリーニング学会誌. 28 (3), 2018, 47-52.
 
13) 南谷幹史ほか. 先天性甲状腺機能低下症マス・スクリーニング運用の各検査施設での状況調査 : 「ガイドライン 2009 (仮称) 」作成に向けて. 日本マススクリーニング学会誌. 19, 2009, 51-7.
 
14) 日本マススクリーニング学会. "平成31年度 新生児スクリーニング検査実施施設一覧表". 2019. http://www.jsms.gr.jp/contents04-01-02.html (2020年1月閲覧)
 
15) Lain, S. et al. Are lower TSH cutoffs in neonatal screening for congenital hypothyroidism warranted? Eur J Endocrinol. 177 (5), 2017, D1-12.
PubMed
16) Deladoey, J. et al. Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Quebec. J Clin Endocrinol Metab. 96 (8), 2011, 2422-9.
PubMed
17) Persani, L. et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. Eur Thyroid J. 7 (5), 2018, 225-37.
PubMed
18) 長崎啓祐ほか. 先天性中枢性甲状腺機能低下症の診療状況の全国調査. 日本マススクリーニング学会誌. 27 (1), 2017, 9-15.
Medical*Online
19) Fujiwara, F. et al. Central Congenital Hypothyroidism Detected by Neonatal Screening in Sapporo, Japan (2000-2004) : It's Prevalence and Clinical Characteristics. Clin Pediatr Endocrinol. 17 (3), 2008, 65-9.
 
20) Zwaveling-Soonawala, N. et al. The severity of congenital hypothyroidism of central origin should not be underestimated. J Clin Endocrinol Metab. 100 (2), 2015, E297-300.
 
21) Kaluarachchi, DC. et al. Congenital hypothyroidism with delayed thyroid-stimulating hormone elevation in premature infants born at less than 30 weeks gestation. J Perinatol. 37 (3), 2017, 277-82.
PubMed
22) Zung, A. et al. Risk factors for the development of delayed tsh elevation in neonatal intensive care unit newborns. Clin Endocrinol Metab. 102 (8), 2017, 3050-5.
PubMed
23) Uchiyama, A. et al. Small for gestational age is a risk factor for the development of delayed thyrotropin elevation in infants weighing less than 2000 g. Clin Endocrinol (Oxf). 89 (4), 2018, 431-6.
PubMed
24) Hashemipour, M. et al. Screening of congenital hypothyroidism in preterm, low birth weight and very low birth weight neonates : A systematic review. Pediatr Neonatol. 59 (1), 2018, 3-14.
PubMed
25) 日本甲状腺学会編. バセドウ病治療ガイドライン 2019. 東京, 南江堂, 2019.
 
26) World Health Organization, United Nations Children's Fund & International Council for the Control of Iodine Deficiency Disorders. Assessment of Iodine Deficiency Disorders and Monitoring their Elimination. 3rd ed. https://apps.who.int/iris/bitstream/handle/10665/43781/9789241595827_eng.pdf (2020年1月閲覧)
 
27) Global scorecard of iodine nutrition in 2019 : in the general population based on median urinary iodine concentration (mUIC) in school-age children (SAC). http://www.ign.org/cm_data/Global_Scorecard_MAP_2019_SAC.pdf (2020年1月閲覧)
 
28) 布施養善ほか. ヨウ素摂取と甲状腺機能, 成長発達との関連に関する研究 : 学童全国調査による日本人のヨウ素摂取状況に関する研究 第3報. 成長科学協会 研究年報. 41, 2017, 57-65.
 
29) 布施養善ほか. ヨード摂取と妊婦及びその出生児の甲状腺機能に関する臨床的研究 : 分娩周辺期のヨウ素代謝の母子間相関について. 成長科学協会 研究年報. 35, 2012, 49-58.
 
30) 日本産科婦人科学会・日本産婦人科医会編. "CQ006 妊娠中に甲状腺疾患が疑われた場合は? " 産婦人科診療ガイドライン : 産科編 2017. 34. http://www.jsog.or.jp/activity/pdf/gl_sanka_2017.pdf (2020年1月閲覧)
 
31) Satoh, M. et al. Thyroid dysfunction in neonates born to mothers who have undergone hysterosalpingography involving an oil-soluble iodinated contrast medium. Horm Res Paediatr. 84 (6), 2015, 370-5.
PubMed
32) 布施養善ほか. ヨード摂取と妊婦及びその出生児の甲状腺機能に関する臨床的研究. 成長科学協会 研究年報. 37, 2013, 33-48.
 
33) Nazeri, P. et al. Breast milk iodine concentration rather than maternal urinary iodine is a reliable indicator for monitoring iodine status of breastfed neonates. Biol Trace Elem Res. 185 (1), 2018, 71-7.
PubMed
34) Fuse, Y. et al. Iodine status of pregnant and postpartum Japanese women : effect of iodine intake on maternal and neonatal thyroid function in an iodine-sufficient area. J Clin Endocrinol Metab. 96 (12), 2011, 3846-54.
 
35) 藤倉かおりほか. 先天性甲状腺機能低下症スクリーニング精密検査時の尿中ヨードについて. 札幌市衛生研究所年報. 45, 2018, 45-9.
 
36) 佐藤英利ほか. 先天性甲状腺機能低下症精密検査対象者における尿中総ヨード測定の意義. 日本マススクリーニング学会誌. 26 (1), 2016, 51-7.
Medical*Online
37) 橘真紀子ほか. 新生児マススクリーニングで先天性甲状腺機能低下症が疑われた例での尿中総ヨウ素の検討. 第52回日本小児内分泌学会学術集会. 2018.
 
38) Farebrother, J. et al. Thyroglobulin is markedly elevated in 6- to 24-month-old infants at both low and high iodine intakes and suggests a narrow optimal iodine intake range. Thyroid. 29 (2), 2019, 268-77.
PubMed
P.100 掲載の参考文献
1) 日本小児内分泌学会マス・スクリーニング委員会. 日本マス・スクリーニング学会. 先天性甲状腺機能低下症マス・スクリーニングガイドライン (2014年改訂版).
 
2) Van Viet, G. et al. "Hypothyroidism in infants and children : neonatal screening". Werner & Ingbar's the thyroid : a fundamental and clinical text. Braverman, LE., Cooper, DS. eds. Philadelphia, Lippincott Williams & Wilkins. 2013, 787-97.
 
3) Maruo, Y. et al. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J Clin Endocrinol Metab. 93, 2008, 4261-7.
 
4) Maruo, Y. et al. Natural course of congenital hypothyroidism by dual oxidase 2 mutations from the neonatal period through puberty. Eur J Endocrinol. 174, 2016, 453-63.
PubMed
5) Macchia, PE. Recent advances in understanding the molecular basis of primary congenital hypothyroidism. Mol Med Today. 6, 2000, 36.
PubMed
6) Krude, H. et al. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest. 109, 2002, 475-80.
PubMed
7) Macchia, PE. et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nature Genet. 19, 1998, 83-86.
 
8) Fujiwara, H. et al. Congenital hypothyroidism caused by a mutation in the Na (+) /I (-) symporter. (Letter) Nature Genet. 16, 1997, 124-25.
 
9) Everett, LA. et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nature Genet. 17, 1997, 411-22.
 
10) 深田修司. サイログロブリン遺伝子異常症. 別冊日本臨床. 内分泌症候群 (第3版) I. 2018, 377-80.
 
11) Abramowicz, MJ. et al. Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. J. Clin. Invest. 90, 1992, 1200-04.
PubMed
12) Narumi, S. et al. Molecular basis of thyroid dyshormonogenesis : genetic screening in populationbased Japanese patients. J Clin Endocrinol Metab. 96, 2011, E1838-42.
PubMed
13) Zheng, X. et al. A Novel c.554+5C > T Mutation in the DUOXA2 Gene Combined with p.R885Q Mutation in the DUOX2Gene Causing Congenital Hypothyroidism. J Clin Res Pediatr Endocrinol. 8 (2), 2016, 224-7.
 
14) Sakurai, A. et al. Structural analysis of human thyroid hormone receptor beta gene. Molec Cell Endocr. 71, 1990, 83-91.
PubMed
15) Maruo, Y. et al. Successful every-other-day liothyronine therapy for severe resistance to thyroid hormone beta with a novel THRB mutation; case report. BMC Endocr Disord. 16, 2016, 1.
PubMed
16) Dumitrescu, AM. et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 74, 2004, 168-75.
 
P.107 掲載の参考文献
1) Fisher, DA. Thyroid function in premature infants : The hypothyroxinemia of prematurity. Clinics in Perinatology. 25, 1998, 999-1014.
PubMed
2) Wilson, JD. et al. Textbook of endocrinology. 9th ed. Philadelphia, Saunders, 1998, 1819p.
 
3) Ahmed, OM. et al. Thyroid hormones states and brain development interactions. Int J Devl Neuroscience. 26 (2), 2008, 147-209.
 
4) Meijer, WJ. et al. Transient hypothyroxinemia associated with developmental delay in very preterm infants. Arch Dis Child. 67, 1992, 944-7.
PubMed
5) Reuss, ML. et al. The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age. N Eng J Med. 334, 1996, 821-7.
 
6) van Wassenaer, AG. et al. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med. 336 (1), 1997, 21-6.
PubMed
7) Osborn, DA. et al. Postnatal thyroid hormones for preterm infants with transient hypothyroxinaemia. Cochrane Database Syst Rev. 1, 2007, CD005945.
PubMed
8) Briet, JM. et al. Neonatal thyroxine supplementation in very preterm children : developmental outcome evaluated at early school age. Pediatrics. 107 (4), 2001, 712-8.
PubMed
9) Rapaport, R. et al. Hypothyroxinemia in the preterm infant : the benefits and risks of thyroxine treatment. J Pediatr. 139 (2), 2001, 182-8.
PubMed
10) La Gamma, EF. et al. Phase 1 trial of 4 thyroid hormone regimens for transient hypothyroxinemia in neonates of of < 28 weeks' gestation. Pediatrics. 124 (2), 2009, e258-e268.
PubMed
11) Ng, SM. et al. A randomized controlled trial of thyroxine in preterm infants under 28 weeks' gestation. Trials. 9, 2008, 17.
PubMed
12) Uchiyama, A. et al. Effect of l-thyroxine supplementation on infants with transient hypothyroxinemia of prematurity at 18 months of corrected age : randomized clinical trial. J Pediatr Endocrinol Metab. 28 (1-2), 2015, 177-82.
 
13) Niwa, F. et al. Hyperthyrotropinemia at 2 weeks of age indicate thyroid dysfunction and predict the occurrence of delayed elevation of thyrotropin in very low birth weight infants. Clin Endocrinol. 77 (2), 2012, 255-61.
PubMed
14) Yamamoto, A. et al. Response to thyrotropin-releasing hormone stimulation tests in preterm infants with transient hypothyroxinemia of prematurity. J Perinatol. 35, 2015, 725-8.
PubMed
15) Jacobs, A. et al. Non-Thyroidal Illness Syndrome in Critically Ill Children : Prognostic Value and Impact of Nutritional Management. Thyroid. 29 (4), 2019, 480-92.
PubMed
16) 日本小児内分泌学会マス・スクリーニング委員会, 日本マス・スクリーニング学会. 先天性甲状腺機能低下症マス・スクリーニングガイドライン (2014年改訂版). http://jspe.umin.jp/medical/files/CH_gui.pdf (2020年1月閲覧)
 
17) Takizawa, F. et al. Two preterm infants with late onset circulatory collapse induced by levothyroxine sodium. Pediatr Int. 52, 2010, e154-e157.
PubMed
18) Kawai, M. et al. National wide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birth-weight infants in Japan. Pediatr Int. 54 (2), 2012, 177-81.
 
19) 河井昌彦. コルチゾールの代謝に及ぼすホルモンの影響. 周産期・新生児ステロイドを使いこなそう!. 京都, 金芳堂, 2018, 83-4.
 
20) レボチロキシンナトリウム錠 チラーヂン(R) S錠. 添付文書. あすか製薬株式会社 2019年11月改訂 (第13版).
 
P.118 掲載の参考文献
1) 河井昌彦. "低血糖症". 新生児医学. 京都, 金芳堂, 2015, 367-76.
 
2) Platt, MW. et al. Metabolic adaptation at birth. Seminars in Fetal and Neonatal Medicine. 10 (4), 2005, 341-50.
 
3) Srinivasan, G. et al. Plasma glucose values in normal neonates : a new look. J Pediatr. 109 (1), 1986, 114-7.
 
4) Stanley, CA. Hypoglycemia in the neonate. Pediatr Endocrinol Rev. Suppl 1, 2006, 76-81.
 
5) Stanley, CA. et al. Re-evaluating "Transitional neonatal hypoglycemia" : Mechanism and implication for management. J Pediatr. 166 (6), 2015, 1520-1525e.
PubMed
6) 河井昌彦. "低血糖症". NICUベッドサイドの診断と治療. 第4版. 京都, 金芳堂, 2016, 263.
 
7) 日本小児内分泌学会, 日本小児外科学会. 先天性高インスリン血症診療ガイドライン. Ver 1.1. 平成29年10月22日. http://jspe.umin.jp/medical/files/guide171015.ver1.1.pdf (2020年2月閲覧)
 
8) 河井昌彦. "新生児期の下垂体機能不全症を疑う主要症候". イラストで見る診る学ぶ新生児内分泌. 大阪, メディカ出版, 2011, 159-61.
 
9) Giurgea, I. et al. Molecular mechanisms of neonatal hyperinsulinism. Horm. Res. 66, 2006, 289-96.
PubMed
10) Stanley, CA. Perspective on the genetics and diagnosis of congenital hyperinsulinism disorders. JCEM. 101 (3), 2016, 815-26.
PubMed
11) 長井静世ほか. 集学的アプローチにより腫瘍核出術をしえた局所性先天性高インスリン血症. 日本小児科学会雑誌. 113 (5), 2009, 838-42.
 
12) Touati, G. et al. Long-term treatment of persistent hypoglycemia of infancy with diazoxide : a retrospective review of 77 cases and efficacy-predicting criteria. Eur J Pediatr. 157 (8), 1998, 628-33.
PubMed
13) 吉田佳代ほか. ジアゾキシド投与を契機に晩期循環不全・動脈管再開通をきたした極低出生体重児の1例. 日本周産期新生児医学会雑誌. 47 (3), 2011, 659-63.
 
14) 丸茂智恵子ほか. 高インスリン血性低血糖症に対しジアゾキシドを使用し, 動脈管開存症・心不全の管理に難渋した極低出生体重児の一例. 日本未熟児新生児学会雑誌, 24 (1), 2012, 143-7.
Medical*Online
15) Yoshida, K. et al. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology. 105 (3), 2014, 166-71.
PubMed
16) Stanley, CA. et al. Metabolic fuel and hormone responses to fasting in newborn infants. Pediatrics. 64 (5), 1979, 613-9.
PubMed
17) Hawdon, JM. et al. Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. Arch Dis Child. 67 (4), 1992, 357-65.
 
P.131 掲載の参考文献
1) Gloyn, AL. et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 350 (18), 2004,1838-49.
PubMed
2) Hattersley, AT. et al. ISPAD Clinical Practice Consensus Guidelines 2018 : The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 19 Suppl 27, 2018, 47-63.
 
3) 稲垣暢也. 日本人における新生児糖尿病発症原因遺伝子異常の実態把握および遺伝子変異部位による薬効変化に関する検討. 厚生労働科学研究費難治性疾患克服研究事業. 平成24年度総括・分担研究報告書. 2012, 6.
 
4) Yorifuji, T. et al. Comprehensive molecular analysis of Japanese patients with pediatric-onset MODY-type diabetes mellitus. Pediatr Diabetes. 13 (1), 2012, 26-32.
PubMed
5) Edghill, EL. et al. Insulin mutation screening in 1,044 patients with diabetes : mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes. 57 (4), 2008, 1034-42.
PubMed
6) de Franco, E. et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes : an international cohort study. Lancet. 386 (9997), 2015, 957-63.
PubMed
7) Mackay, DJ. et al. Transientneonataldiabetes mellitus type 1. Am J Med Genet C Semin Med Genet. 154C (3), 2010, 335-42.
PubMed
8) Docherty, LE. et al. Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype-phenotype correlation in an international cohort of patients. Diabetologia. 56 (4), 2013, 758-62.
 
9) Yorifuji, T. et al. Chromosome 6q24-related diabetes mellitus. Clinical Pediatric Endocrinology. 27 (2), 2018, 59-65.
PubMed
10) Busiah, K. et al. Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus : a prospective cohort study. Lancet Diabetes Endocrinol. 1 (3), 2013, 199-207.
PubMed
11) Lang, V, et al. The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. Pharmgenomics Pers Med. 3, 2010, 145-61.
PubMed
12) Bowman, P. et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations : an international cohort study. Lancet Diabetes Endocrinol. 6 (8), 2018, 637-46.
PubMed
13) Stoy, J. et al. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene . Rev Endocr Metab Disord. 11 (3), 2010, 205-15.
PubMed
14) Rabbone, I. et al. Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis. Acta Diabetol. 53 (4), 2016, 559-65.
PubMed
15) Polak, M. et al. Neonatal diabetes mellitus : a disease linked to multiple mechanisms. Orphanet Journal of Rare Diseases. 2, 2007, 12.
PubMed
16) Pinelli, L. et al. Insulin pump therapy in children and adolescents with type 1 diabetes : the Italian viewpoint. Acta Biomed. 79, 2008, 57-64.
PubMed
17) Rabbone, I. et al. Insulin therapy in neonatal diabetes mellitus : a review of the literature. Diabetes Res Clin Pract. 129, 2017, 126-135.
PubMed
18) Pearson, ER. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 355, 2006, 467-77.
PubMed
19) Rafiq, M. et al. Effectivetreatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 3, 2008, 204-9.
 
20) Diabetes Genes. Exeter. http://www.diabetesgenes.org/ (2019年11月閲覧)
 
21) Bowman, P. et al. Cognitive, Neurological, and Behavioral Features in Adults with KCNJ11 Neonatal Diabetes. Diabetes Care. 42 (2), 2019, 215-224.
PubMed
P.141 掲載の参考文献
1) Takemoto, Y. et al. Japanese secular trends in birthweight and the prevalence of low birthweight infants during the last three decades : A population-based study. Sci Rep. 6, 2016, 31396.
PubMed
2) 日本小児科学会新生児委員会. 新生児に関する用語についての勧告. 日本小児科学会雑誌. 98, 1994, 1946-50.
 
3) 厚生労働省. 平成30年 わが国の人口動態 : 平成28年までの動向. 2018年3月28日. 13. https://www.mhlw.go.jp/toukei/list/dl/81-1a2.pdf (2019年11月閲覧)
 
4) Clayton, PE. et al. Management of the child born small for gestational age through to adulthood : a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 92 (3), 2007, 804-10.
PubMed
5) Lee, AC. et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health. 1 (1), 2013, e26-36.
PubMed
6) 板橋家頭夫ほか. 日本小児科学会新生児員会. 日本小児科学会新生児委員会報告. 新しい在胎期間別出生時体格標準値の導入について. 日本小児科学会雑誌. 114, 2010, 1771-806.
 
7) Barker, DJ. et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X) : relation to reduced f. et al growth. Diabetologia. 36 (1), 1993, 62-7.
 
8) Gluckman, PD. et al. Early life events and their consequences for later disease : a life history and evolutionary perspective. Am J Hum Biol. 19 (1), 2007, 1-19.
 
9) Singhal, A. The role of infant nutrition in the global epidemic of non-communicable disease. 75 (2), 2016, 162-8.
PubMed
10) Imura, H. Life course health care and preemptive approach to non-communicable diseases. Proc Jpn Acad Ser B Phys Biol Sci. 89 (10), 2013, 462-73.
PubMed
11) Gluckman, PD. et al. Predictive adaptive responses and human evolution. Trends EcolEvol. 20 (10), 2005, 527-33.
 
12) Hanson, M. et al. Developmental plasticity and developmental origins of non-communicable disease : theoretical considerations and epigenetic mechanisms. Prog Biophys Mol Biol. 106 (1), 2011, 272-80.
PubMed
13) 中野有也. DOHaD研究の展望と課題. 実験医学. 35 (19), 2017, 3265-9.
Medical*Online
14) Woods, LL. et al. Programming of adult blood pressure by maternal protein restriction : role of nephrogenesis. Kidney Int. 65 (4), 2004, 1339-48.
PubMed
15) Remacle, C. et al. Intrauterine programming of the endocrine pancreas. Diabetes Obes Metab. Suppl 2, 2007, 196-209.
 
16) Weinstock, M. The potential influence of maternal stress hormones on development and mental health of the offspring. Brain Behav Immun. 19 (4), 2005, 296-308.
 
17) Kapoor, A. et al. Fetal programming of hypothalamo-pituitary-adrenal function : prenatal stress and glucocorticoids. J Physiol. 572 (Pt 1), 2006, 31-44.
 
18) 久保田健夫ほか. "エピジェネティクスとDOHaD". DOHaDその基礎と臨床. 板橋家頭男編. 東京, 金原出版, 2008, 83-9.
 
19) Heijmans, BT. et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA. 105 (44), 2008, 17046-9.
PubMed
20) Lillycrop, KA. et al. Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR alpha promoter of the offspring. Br J Nutr. 100 (2), 2008, 278-82.
PubMed
21) Harder, T. et al. Where is the evidence that low birthweight leads to obesity? Lancet. 369 (9576), 1859.
PubMed
22) Schellong, K. et al. Birth weight and long-term overweight risk : systematic review and a meta analysis including 643,902 persons from 66 studies and 26 countries globally. PLoS One. 7 (10), 2012, e47776.
 
23) Gianni, ML. et al. Adiposity in small for gestational age preterm infants assessed at term equivalent age. Arch Dis Child Fetal Neonatal Ed. 94 (5), 2009, F368-72.
PubMed
24) Tsubahara, M. et al. Glucose metabolism soon after birth in very premature infants with small- and appropriate-for-gestational-age birth weights. Early Hum Dev. 88 (9), 2012, 735-8.
PubMed
25) Hofman, PL. et al. Premature birth and later insulin resistance. N Engl J Med. 51 (21), 2004, 2179-86.
 
26) Mericq, V. et al. Longitudinal changes in insulin sensitivity and secretion from birth to age three years in small- and appropriate-for-gestational-age children. Diabetologia. 48 (12), 2005, 2609-14.
PubMed
27) Darendeliler, F. et al. Insulin resistance and body composition in preterm born children during prepubertal ages. Clin Endocrinol (Oxf). 68 (5), 2008, 773-9.
PubMed
28) Poindexter, BB. et al. Early provision of parenteral amino acids in extremely low birth weight infants : relation to growth and neurodevelopmental outcome. J Pediatr. 148 (3), 2006, 300-5.
PubMed
29) Itabashi, K. et al. Longitudinal follow-up of height up to five years of age in infants born preterm small for gestational age ; comparison to full-term small for gestational age infants. Early Hum Dev. 83 (5), 2007, 327-33.
PubMed
30) Uthaya, S. et al. Altered adiposity after extremely preterm birth. Pediatr Res. 57 (2), 2005, 211-5.
PubMed
31) Markopoulou, P. et al. Preterm birth as a risk factor for metabolic syndrome and cardiovascular disease in adult life : A systematic review and meta-analysis. J Pediatr. 210, 2019, 69-80.
PubMed
32) Balasuriya, CND. et al. Metabolic Outcomes in Adults Born Preterm with very low Birthweight or Small for Gestational Age at Term : A Cohort Study. J Clin Endocrinol Metab. 103 (12), 2018, 4437-46.
PubMed
33) Ip, S. et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess. 153, 2007, 1-186.
PubMed
34) 厚生労働省. 授乳・離乳の支援ガイド (2019年改訂版). 2019. https://www.mhlw.go.jp/stf/newpage_04250.html (2019年11月閲覧)
 
35) Stiemsma, LT. et al. The Role of the Microbiome in the Developmental Origins of Health and Disease. Pediatrics. 141 (4), 2018, e20172437.
PubMed
36) Murphy, R. et al. Antibiotic treatment during infancy and increased body mass index in boys : an international cross-sectional study. Int J Obes (Lond). 38 (8), 2014, 1115-9.
PubMed
37) Regan, FM. et al. The impact of early nutrition in premature infants on later childhood insulin sensitivity and growth. Pediatrics. 118 (5), 2006, 1943-9.
PubMed
38) Singhal A. et al. Low nutrient intake and early growth for later insulin resistance in adolescents born preterm. Lancet. 361 (9363), 2003, 1089-97.
PubMed
P.154 掲載の参考文献
1) 下風朋章ほか. 処置時の皮膚保護対策. 周産期医学. 42 (12), 2012, 1673-6.
Medical*Online
2) Bellini, C. et al. Lymphodynamics in the fetus and newborn. Lymphology. 39 (3), 2006, 110-7.
PubMed
3) Gleason, CA. et al. "Fluid, Electrolyte and Acid-Base Balance". Avery's Diseases of the Newborn. 10th ed. Philadelphia, Elsevier. 2018. 368-89.
 
4) Ishiguro, A. et al. Changes in skin and subcutaneous perfusion in very-low-birth-weight infants during the transitional period. Neonatology. 100 (2), 2011, 162-8.
PubMed
5) Vieux, R. et al. Glomerular filtration rate reference values in very preterm infants. Pediatrics. 125 (5), 2010, e1186-92.
PubMed
6) Shimokaze, T. et al. Late-onset glucocorticoid-responsive circulatory collapse in preterm infants : clinical characteristics of 14 patients. Tohoku J Exp Med. 235 (3), 2015, 241-8.
PubMed
7) Shimokaze, T. et al. Increased incidence of late-onset circulatory collapse after changing clinical practice : A retrospective investigation of causative factors. Am J Perinatol. 32, 2015, 1169-76.
PubMed
8) Baraton, L. et al. Impact of changes in serum sodium levels on 2-year neurologic outcomes for very preterm neonates. Pediatrics. 124 (4), 2009, e655-61.
PubMed
9) Burnell, JM. et al. The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest. 35 (9), 1956, 935-9.
PubMed
10) Tuhan, HU. et al. Cross-reactivity of adrenal steroids with aldosterone may prevent the accurate diagnosis of congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 28 (5-6), 2015, 701-4.
 
11) Shimokaze, T. et al. Heparin-induced hyperkalemia in an extremely-low-birth-weight infant : a case report. J Clin Res Pediatr Endocrinol. 6 (2), 2014, 125-8.
 
12) Shimokaze, T. et al. Blood potassium and urine aldosterone after doxapram therapy for preterm infants. Journal of Perinatology. 38 (6), 2018, 702-7.
PubMed
13) Christian, D. et al. Refeeding Syndrome. Pediatrics in Review. 37 (12), 2016, 516-23.
 
14) Mizumoto, H. et al. Refeeding syndrome in a small-for-dates micro-preemie receiving early parenteral nutrition. Pediatrics International. 54 (5), 2012, 715-7.
 
15) Braden, GL. et al. Ritodrine- and terbutaline-induced hypokalemia in preterm labor : mechanisms and consequences. Kidney Int. 51 (6), 1997, 1867-75.
PubMed
16) Tanaka, K. et al. Early-onset neonatal hyperkalemia associated with maternal hypermagnesemia : a case report. BMC Pediatrics. 18 (1), 2018, 55.
PubMed
17) Himathongkam, T. et al. Potassium-aldosterone-renin interrelationships. J Clin Endocrinol Metab. 41 (1), 1975, 153-9.
PubMed
18) Wu, CH. et al. Comparison of 24-h urinary aldosterone level and random urinary aldosterone-tocreatinine ratio in the diagnosis of primary aldosteronism. PloS One. 28 (6), 2013, e67417.
 
19) West, ML. et al. Development of a test to evaluate the transtubular potassium concentration gradient in the cortical collecting duct in vivo. Mineral and electrolyte metabolism. 12 (4), 1986, 226-33.
PubMed
20) Kamel, KS. et al. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium : an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. 20 (5), 2011, 547-54.
PubMed
21) Hollander-Rodriguez, JC. et al. Hyperkalemia. Am Fam Physician. 73 (2), 2006, 283-90.
PubMed
22) Baraton, L. et al. Impact of changes in serum sodium levels on 2-year neurologic outcomes for very preterm neonates. Pediatrics. 124 (4), 2009, e655-61.
PubMed
23) Passmore, AP. et al. Caffeine and hypokalemia. Ann Intern Med. 105 (3), 1986, 468.
PubMed
24) Wong, CS. et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 336, 1990, 1396-9.
PubMed
P.167 掲載の参考文献
1) Kopic, S. et al. Gastric acid, calcium absorption, and their impact on bone health. Physiol Rev. 93 (1), 2013, 189-268.
 
2) Kovacs, CS. Bone development and mineral homeostasis in the fetus and neonate : roles of the calciotropic and phosphotropic hormones. Physiol Rev. 94 (4), 2014, 1143-218.
PubMed
3) Kovacs, CS. et al. Fetal parathyroids are not required to maintain placental calcium transport. J Clin Invest. 107 (8), 2001, 1007-15.
 
4) Simmonds, CS. Parathyroid hormone regulates fetal-placental mineral homeostasis. J Bone Miner Res. 25 (3), 2010, 594-605.
PubMed
5) Kovacs, CS. et al. Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. Proc Natl Acad Sci USA. 93 (26), 1996, 15233-8.
PubMed
6) Venkataraman, PS. et al. Early neonatal hypocalcemia in extremely preterm infants. High incidence, early onset, and refractoriness to supraphysiologic doses of calcitriol. Am J Dis Child. 140 (10), 1986, 1004-8.
PubMed
7) Yagi, H. et al. Role of TBX1 in human del22q11.2 syndrome. Lancet. 362 (9393), 2003, 1366-73.
PubMed
8) Mayr, B. Genetics in endocrinology : Gain and loss of function mutations of the calcium-sensing receptor and associated proteins : current treatment concepts. Eur J Endocrinol. 174 (5), 2016, R189-208.
 
9) Whyte, MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 12 (4), 2016, 233-46.
PubMed
10) Stockler, S. et al. Pyridoxine dependent epilepsy and antiquitin deficiency : clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 104 (1-2), 2011, 48-60.
 
11) 日本小児内分泌学会低ホスファターゼ症診療ガイドライン作成委員会. 低ホスファターゼ症診療ガイドライン. 2019. https://jspe.umin.jp/medical/gui.html (2019年11月閲覧)
 
12) Whyte, MP. et al. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. J Clin Endocrinol Metab. 101 (1), 2016, 334-42.
PubMed
13) Kishnani, PS. et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 122 (1-2), 2017, 4-17.
 
P.174 掲載の参考文献
1) 楠田聡. "早産児と骨代謝". 小児の骨の発達とその異常性. 藤枝憲二監. 東京, 診断と治療社, 2008, 64-8.
 
2) Greenblatt, MB. et al. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem. 63 (2), 2017, 464-74.
PubMed
3) Wheater, G. et al. The clinical utility of bone marker measurements in osteoporosis. J Transl Med. 11 (1), 2013, 201.
 
4) Mitchell, SM. et al. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr. 9, 2009, 47.
PubMed
5) Harrison, CM. et al. Osteopenia of prematurity : national survey and review of practice. Acta Paediatr. 97 (4), 2007, 407-13.
 
6) Dowa, Y. et al. Screening for the secondary hyperparathyroidism in osteopathy of prematurity. Pediatr Int. 58, 2016, 988-92.
PubMed
7) 児玉浩子ほか. 亜鉛欠乏症の診療指針 2016. 日本臨床栄養学会雑誌. 38 (2), 2016, 104-48.
Medical*Online
8) Itabashi, K. et al. Estimated nutritional intake on the reference growth curves for extremely low birth weight infants. Pediatr Int. 41 (1), 1999, 70-7.
PubMed
9) 河井昌彦. "低Ca血症・早産児骨減少症". NICUベッドサイドの診断と治療. 第4版. 京都, 金芳堂, 2016, 270-5.
 
10) Catache, M. et al. Role of plasma and urinary calcium and phosphorus measurements in early detection of phosphorus deficiency in very low birthweight infants. Acta Paediatr. 92 (1), 2003, 76-80.
PubMed
11) 河井昌彦. "カルシウムとリンの微妙な関係…ご存じですか?". NICUのギ・モ・ン 98+2. 京都, 金芳堂, 2016, 128-30.
 
12) Holick, MF. et al. Evaluation, treatment, and prevention of vitamin D deficiency : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 96 (7), 2011, 1911-30.
PubMed
P.198 掲載の参考文献
1) Hughes, IA. et al. Consensus statement on management of intersex disorders. Arch Dis Child. 91 (7), 2006, 554-63.
PubMed
2) 緒方勤ほか. "性分化異常症の管理に関する合意見解". 日本小児科学会雑誌. 112 (3), 2008, 565-78.
 
3) 川井正信. "DSDの分類". みんなで考える性分化疾患 : 本人と養育者と医療者のために. 位田忍ほか編. 東京, 診断と治療社, 2019, 15-22.
 
4) 緒方勤. "性分化の基礎知識". 性分化疾患の診断と治療. http://jspe.umin.jp/medical/research.html (2019年11月閲覧)
 
5) Achermann, JC. et al. "Pediatric Disorders of Sex Development". Williams Textbook of Endocrinology. Melmed, S. et al. ed. Philadelphia, Elsevier, 2016, 893-963.
 
6) Wilhelm, D. et al. Mammalian sex determination and gonad development. Curr Top Dev Biol. 106, 2013, 89-121.
PubMed
7) Prader, A. Der genitalbefund beim pseudohermaphroditismus femininus der kengenitalen adrenogenitalen syndroms. Helv Paediatr Acts. 9, 1954, 231-48.
 
8) Quigley, CA. et al. Androgen receptor defects : historical, clinical, and molecular perspectives. Endocr Rev. 16 (3), 1995, 271-321.
PubMed
9) Ahmed, SF. et al. The role of a clinical score in the assessment of ambiguous genitalia. BJU International. 85 (1), 2000, 120-4.
PubMed
10) Ishii, T. et al. A cross-sectional growth reference and chart of stretched penile length for Japanese boys aged 0-7 years. Horm Res Pediatr. 82 (6), 2014, 388-93.
 
11) 横谷進ほか. 未熟児・新生児・乳児・幼児における陰茎および陰核の大きさの計測. ホルモンと臨床. 31 (12), 1983, 1215-20.
 
12) Grinspon, RP. et al. Anti-mullerian hormone and Sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr. 73 (2), 2010, 81-92.
PubMed
13) Kuiri-Hanninen, T. et al. Activation of the hypothalamic-pituitary-gonadal axis in infancy : minipuberty. Horm Res Pediatr. 82 (2), 2014, 73-80.
 
14) Bergada, I. et al. Time course of the serum gonadotropin surge, inhibins, and anti-mullerian hormone in normal newborn males during the first month of life. J Clin Endocrinol Metab. 91 (10), 2006, 4092-8.
 
15) 室谷浩二ほか. 新生児期血中テストステロン測定のピットフォール. 第40回日本小児内分泌学会学術集会. 2006.
 
16) 日本小児内分泌学会性分化委員会. 性分化疾患初期対応の手引き. http://jspe.umin.jp/medical/files/seibunkamanual_2011.1.pdf (2019年11月閲覧)
 
17) 久住浩美ほか. 性腺の画像診断. 小児科診療. 65 (10), 2002, 1629-37.
Medical*Online
18) 日本小児内分泌学会. 遺伝子診断委員会〔会員専用ページ内〕. http://jspe.umin.jp (2019年11月閲覧)
 
19) 石井智弘. "性分化疾患". 小児疾患診療のための病態生理 2. 改訂5版. 『小児内科』『小児外科』編集委員会編. 東京, 東京医学社, 2015, 447-56.
 
20) de Vrie, A. et al. Disorders of sex development and gender identity outcome in adolescence and adulthood : understanding gender identity development and its clinical implications. Pediatr Endocrinol Rev. 4 (4), 2007, 343-51.
 
21) 緒方勤. "性分化異常". 小児内分泌疾患鑑別診断チャート. 藤枝憲二編. 東京, 診断と治療社, 2009, 80.
 
22) Choi, JH. Differential diagnosis of disorders of sex development (DSD) by molecular genetic analyses. Ann Pediatr Endocrinol Metab. 17 (3), 2012, 137-44.
 
23) 日本小児内分泌学会. 性分化・副腎疾患委員会. http://jspe.umin.jp/medical/research.html (2019年11月閲覧)
 
24) 松山聡子ほか. "DSDで出生届はどのように出すのか? 性別を変える場合の手続きは? (法律制度). みんなで考える性分化疾患 : 本人と養育者と医療者のために. 位田忍ほか編. 東京, 診断と治療社, 2019, 88-91.
 
25) ネクスDSDジャパン. https://www.nexdsd.com (2019年11月閲覧)
 
P.212 掲載の参考文献
1) 山口清次. タンデムマス法を導入した新生児マススクリーニングの新しい体制. 新生児マススクリーニングの今. 日本医事新報. 4838, 2017, 25-34.
 
2) Shibata, N. et al. Diversity in the incidence and spectrum of organic acidemias, fatty acid oxidation disorders, and amino acid disorders in Asian countries : selective screening vs. expanded newborn screening. Mol Genet Met Rep, 16, 2018, 5-10.
 
3) 山口清次編. よくわかる新生児マススクリーニングガイドブック. 診断と治療社, 東京, 2019, 220p.
 
4) 山口清次編. タンデムマス・スクリーニングガイドブック. 診断と治療社, 東京, 2013, 152p.
 
5) 但馬剛. 新生児マススクリーニング対象疾患の診断と治療. 新生児マススクリーニングの今. 日本医事新報, 4838, 2017, 35-43.
 
6) 迫田麻莉, 川目裕. 私信. 2011.
 
7) 先天代謝異常学会編. 新生児マススクリーニング対象疾患等診療ガイドライン. 診断と治療社, 東京, 2015, 318p.
 
8) 日本小児内分泌学会編. 小児内分泌学会ガイドライン集. 東京, 中山書店, 2017, 325p.
 
9) 大浦敏博. 治療用特殊ミルクの現状と安定供給上の問題点. 新生児マススクリーニングの今. 日本医事新報, 4838, 2017, 44-50.
 
10) 山口清次編. よくわかる新生児マススクリーニングガイドブック. 診断と治療社, 東京, 2019, 178.
 
11) 山口清次. タンデムマス・スクリーニングの効果と課題. 公衆衛生, 82 (2), 2018, 132-7.
 
12) 花井潤師ほか. タンデムマス検査データWeb解析システムの有用性について. 日本マススクリーニング学会誌. 27 (1), 2017, 35-42.
Medical*Online
P.224 掲載の参考文献
1) 吉田忍. "どのような症状から先天代謝異常症を疑うか? ". 小児科臨床ピクシス 23 見逃せない先天代謝異常. 五十嵐隆総編集, 高柳正樹専門編集. 東京, 中山書店, 2010, 74-77.
 
2) Morrison, WE. et al eds. Rogers' Handbook of Pediatric Intensive Care. 5th ed. Wolters Kluwer, 2017, 623.
 
3) チョッケ & ホフマン原著. 松原洋一監訳. 小児代謝疾患マニュアル. 改訂第2版. 東京, 診断と治療社, 2013, 1-16.
 
4) Chapman, KA. et al. Acute management of propionic academia. Mol Genet Metab. 105, 2012, 16-25.
 
5) Haberle, J. et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 7, 2012, 32.
PubMed
6) Baumgartner, MR. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic academia. Orphanet J Rare Dis. 9, 2014, 130.
 
7) Enns, GM. et al. Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders. N Engl J Med. 356, 2007, 2282-92.
PubMed
8) Bachmann, C. Outcome and survival of 88 patients with urea cycle disorders : a retrospective evaluation. Eur J Pediatr. 162, 2003, 410-16.
PubMed
9) Omata, T. et al. Drugs indicated for mitochondrial dysfunction as treatments for acute encephalopathy with onset of febrile convulsive status epileptics. J Neurol Sci. 360, 2016, 57-60.
PubMed
10) サム(R) 点滴静注セット. 添付文書 http://www.info.pmda.go.jp/go/pack/3399400X1035_1_04/ (2020年1月閲覧)
 
11) Iyer, H. et al. Coma, hyperammonemia, metabolic acidosis, and mutation : Lessons learned in the acute management of late onset urea cycle disorders. Hemodial Int. 16, 2012, 95-100.
PubMed
12) Wendell, LC. et al. Successful Management of Refractory Intracranial Hypertension from Acute Hyperammonemic Encephalopathy in a Woman with Ornithine Transcarbamylase Deficiency. Neurocrit Care. 13, 2010, 113-17.
 
13) Munnich, A. et al. Clinical presentations and laboratory investigations in respiratory chain deficiency. Eur J Pediatr. 155, 1996, 262-74.
PubMed
14) グリポーゼ(R) 注適正使用のお願い. https://www.fuso-pharm.co.jp/cnt/seihin/pdf/glypose.pdf (2020年1月閲覧)
 
15) 日本ミトコンドリア学会編集. "ミトコンドリア病の栄養療法". ミトコンドリア病診療マニュアル 2017. 東京, 診断と治療社, 2017, 17-18.
 
P.235 掲載の参考文献
1) 平松祐司ほか. 日本糖尿病・妊娠学会と日本糖尿病学会との合同委員会. 妊娠中の糖代謝異常と診断基準の統一化について. 糖尿病. 58 (10), 2015, 801-3.
 
2) 白川嘉継. "糖尿病母体から出生した児". 周産期医学必修知識. 第5版. 周産期医学増刊号. 31, 2001, 410-1.
 
3) Nold, JL. et al. Infants of diabetic mothers. Pediatr. Clin North Am. 51, 2004, 619-37.
PubMed
4) Fukatsu, M. et al. Diagnosis and potential management of gestational diabetes mellitus using the International association of diabetes and pregnancy study groups criteria. J Obstet Gynaecol Res. 43 (2), 2017, 272-80.
PubMed
5) HAPO study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. New Engl J Med. 358 (19), 2008, 1991-2002.
 
6) HAPO study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome (HAPO) study : associations with neonatal anthropometrics. Diabetes. 58 (2), 2009, 453-9.
 
7) International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 33 (3), 2010, 676-82.
PubMed
8) Hay, WW Jr. Care of the infant of the diabetic mother. Curr Diab Rep. 12 (1), 2012, 4-15.
PubMed
9) Son, GH. et al. Maternal serum triglycerides as predictive factors for large-for-gestational age newborns in women with gestational diabetes mellitus. Acta Obstet Gynecol Scand. 89 (5), 2010, 700-4.
PubMed
10) Fanaroff, AA. et al. Neonatal-perinatal medicine. 8th ed. Philadelphia, Mosby-Elsevier, 2006, 1472-9.
 
11) Mills, JL. et al. Malformations in infants of diabetic mother occurred before the seventh gestational week : implication for treatment. Diabetes. 28, 1979, 292-9.
PubMed
12) Miller, E. et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med. 304 (22), 1981, 1331-4.
PubMed
13) Ellis, H. et al. Neonatal small left colon syndrome in the offspring of diabetic mothers-an analysis of 105 children. J Pediatr Surg. 44 (12), 2009, 2343-6.
 
14) Gutgesell, HP. et al. Characterization of the cardiomyopathy in infants of diabetic mothers. Circulation. 61 (2), 1980, 441-50.
PubMed
15) 佐中眞由実. 母体の糖尿病. 周産期医学. 35, 2005, 1701-4.
 
16) Rizzo, TA. et al. Early malnutrition and child neurobehavioral development : insights from the study of children of diabetic mothers. Child Dev. 68, 1997, 26-38.
 
17) Hitaka, D. et al. Neonatal outcomes of very low birthweight infants born to mothers with hyperglycaemia in pregnancy : a retrospective cohort study in Japan. BMJ Paediatr Open. 3 (1), 2019, e000491.
PubMed
18) 百渓尚子. 母体の甲状腺疾患. 周産期医学. 35, 2005, 1695-1700.
 
19) Alexander, EK. et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 27 (3), 2017, 315-89.
PubMed
20) 松浦信夫. "新生児甲状腺機能亢進症と甲状腺中毒症". 内分泌症候群 I. 第2版. 別冊日本臨牀. 2006, 271-5 (新領域別症候群シリーズ).
 
21) Oden, J. et al. Neonatal thyrotoxicosis and persistent pulmonary hypertension necessitating extracorporeal life support. Pediatrics. 115, 2005, e105-8.
PubMed
22) 佐々木望. 甲状腺機能異常の母体から出生した児. 周産期医学. 31, 2001, 412-3.
 
23) 上條桂一. "妊娠時のバセドウ病の診断に甲状腺刺激ホルモン受容体抗体を測定する意味は何ですか? ". 妊娠と甲状腺機能異常症. 森昌朋編. 大阪, メディカルレビュー社, 2013, 59-62.
 
24) 松浦信夫. 母体甲状腺疾患と新生児甲状腺機能異常. 周産期医学. 35, 2005, 1613-6.
 
25) Anselmo, J. et al. Fetal loss associated with excess thyroid hormone exposure. JAMA. 292, 2004, 691-5.
PubMed
26) Haddow, JE. et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 341, 1999, 549-55.
PubMed
27) Piefnger, H. et al. Hypocalcemic tetany in the newborn as a manifestation of unrecognized maternal primary hyperparathyroidism. Wien Klin Wochenschr. 119, 2007, 129-31.
 
28) Korkmaz, HA. et al. Neonatal seizure as a manifestation of unrecognized maternal hyperparathyroidism. J Clin Res Pediatr Endocrinol. 5 (3), 2013, 206-8.
PubMed
P.242 掲載の参考文献
1) Seri, I. Management of hypotension and low systemic blood flow in the very low birth weight neonate during the first postnatal week. J Perinatol. 26 (Suppl 1), 2006, S8-S13.
 
2) Ng, PC. et al. Refractory hypotension in preterm infants with adrenocortical insufficiency. Arch Dis Child Fetal Neonatal Ed. 84, 2001, F122-F124.
PubMed
3) Shimokaze, T. et al. Late-onset glucocorticoid-responsive circulatory collapse in preterm infants : Clinical characteristics of 14 patients. Tohoku J Exp Med. 235 (3), 2015, 241-8.
PubMed
4) Kawai, M. et al. Nationwide surveillance of circulatory collapse associated with levothyroxine administration in very-low-birth-weight infants in Japan. Pediatr Int. 54 (2), 2012, 177-81.
PubMed
5) Watterberg, KL. et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia : a multicenter trial. Pediatrics. 114 (6), 2004, 1649-57.
PubMed
6) Garland, JS. et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates : a randomized trial. Pediatrics. 104 (1 Pt 1), 1999, 91-9.
 
7) Ng, PC. et al. A prospective longitudinal study to estimate the "adjusted cortisol percentile" in preterm infants. Pediatr Res. 69 (6), 2011, 511-6.
PubMed
8) Niwa. F. et al. Limited response to CRH stimulation tests at two weeks of age in preterm infants born at less than 30 weeks of gestational age. Clin Endocrinol. 78 (5), 2013, 724-9.
 
9) Kawai, M. Late onset circulatory collapse of prematurity. Pediatr Int. 59 (4), 2017, 391-6.
PubMed
10) Kusuda, S. et al. Trends in morbidity and mortality among very-low-birth-weight infants from 2003 to 2008 in Japan. Pediatr Res. 72, 2012, 531-8.
PubMed
11) 河井昌彦. "早産児晩期循環不全症". 新生児医学. 京都, 金芳堂, 2015, 383-5.
 
12) Washio, Y. et al. Hemodynamic analysis in infants with late-onset circulatory collapse. Pediatr Inter. 55, 2013, 582-8.
 
13) Iwanaga, K. et al. CRH stimulation tests for the infants with relative adrenal insufficiency. Clin Endocrinol. 87, 2017, 660-4.
PubMed
14) 河井昌彦. "ステロイド療法におけるピットホール". 周産期・新生児ステロイドを使いこなそう!. 京都, 金芳堂, 2018, 67-97.
 
15) Halliday, HL. et al. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systemic reviews. CD001146. 2009.
 
16) Halliday, HL. et al. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systemic Reviews. CD001145. 2009.
 
17) Moreno, R. et al. Time course of organ failure in patients with septic shock treated with hydrocortisone; results of the Corticus study. Intensive Care Med. 37 (11), 2011, 1765-72.
PubMed
18) Stewart, PM. et al. "The adrenal cortex." Melmed, S. et al. eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia, Saunders, 2011, 496.
 
19) Nakanishi, H. et al. Clinical characterization and long-term prognosis of neurological development in preterm infants with late-onset circulatory collapse. J Perinatol. 30, 2010, 751-6.
PubMed
P.251 掲載の参考文献
1) Roberts, D. et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 3 (3), 2017, 10.1002/14651858.CD004454.pub3.
 
2) Lee, BH. et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics. 117 (5), 2006, 1503-10.
PubMed
3) 日本産科婦人科学会・日本産婦人科医会編. "CQ302 切迫早産の診断と管理の注意点は? ". 産婦人科診療ガイドライン : 産科編 2017. 東京, 日本産科婦人科学会, 2017, 152-5.
 
4) Rojas-Reyes, MX. et al. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. (3), 2012, 10.1002/14651858.CD000510.
 
5) Cheong, JLY. et al. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol. 42 (7), 2018, 478-84.
PubMed
6) Jensen, EA. et al. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res. A Clin Mol Teratol. 100 (3), 2014, 145-57.
PubMed
7) "712 CLD at 28d". Analysis results on infants born in 2003-2016. 1-32. http://plaza.umin.ac.jp/nrndata/reports/nrn1_2003_2016.pdf (2020年2月閲覧)
 
8) Northway, WH Jr. et al. Pulmonary disease following respirator therapy of hyaline-membrane disease : bronchopulmonary dysplasia. N Engl J Med. 276 (7), 1967, 357-68.
PubMed
9) 長和俊ほか. 肺サーファクタント補充時代における慢性肺疾患危険因子のロジスティック回帰解析. 日本小児科学会雑誌. 98 (10), 1994, 1894-901.
 
10) Jobe, AH. et al. Can we define bronchopulmonary dysplasia?. J Pediatr. 188, 2017, 19-23.
 
11) Namba, F. et al. Bubbly and cystic appearance in chronic lung disease : Is this diagnosed as Wilson-Mikity syndrome? Pediatr Int. 58 (4), 2016, 251-3.
PubMed
12) Jobe, AH. et al. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 163 (7), 2001, 1723-9.
PubMed
13) Ehrenkranz, RA. et al. Validation of the national institutes of health consensus definition of bronchopulmonary dysplasia. Pediatrics. 116 (6), 2005, 1353-60.
PubMed
14) Avery, GB. et al. Controlled trial of dexamethasone in respiratory dependent infants with bronchopulmonary dysplasia. Pediatrics. 75 (1), 1985, 106-11.
 
15) Yeh, TF. et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 350 (13), 2004, 1304-13.
PubMed
16) American Academy of Pediatrics. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 126 (4), 2010, 800-8.
PubMed
17) Nye, J. Postnatal corticosteroids in the treatment of chronic lung disease in the preterm infant : past, present, and future. Neonatal Netw. 26 (5), 2007, 293-9.
PubMed
18) 楠田聡. "早産児に対するステロイドホルモン投与のポイント". 周産期救急のコツと落とし穴. 岡村州博編. 東京, 中山書店, 2004, 40-1.
 
19) Doyle, LW. et al. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst. Rev,10 (10), 10.1002/14651858.CD001146.pub5.
 
20) Baud, O. et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC) : a double-blind, placebo-controlled, multicentre, randomisedtrial. Lancet. 387 (10030), 2016, 1827-36.
 
21) Doyle, LW. et al. Late (> 7 Days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 10 (10), 10.1002/14651858.CD001145.pub4.
 
22) Shah, VS. et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev. 1 (1), 2017, 10.1002/14651858.CD001969.pub4.
 
P.262 掲載の参考文献
1) Liggins, GC. et al. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 50 (4), 1972, 515-25.
PubMed
2) Crowley, P. et al. The effects of corticosteroid administration before preterm delivery : an overview of the evidence from controlled trials. Br J Obstet Gynaecol. 97 (1), 1990, 11-25.
PubMed
3) 日本産科婦人科学会・日本産婦人科医会 編集・監修. "CQ302 切迫早産の診断と管理の注意点は? ". 産婦人科診療ガイドライン : 産科編 2017. 東京, 日本産科婦人科学会事務局, 2017, 152-7.
 
4) Roberts, D. et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 3 (3), 2017, 10.1002/14651858.CD004454.pub3.
 
5) Jobe, AH. et al. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 178 (5), 1998, 880-5.
PubMed
6) Ikegami, M. et al. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med. 156 (1), 1997, 178-84.
PubMed
7) Braun, T. et al. Growth restricting effects of a single course of antenatal betamethasone treatment and the role of human placental lactogen. Placenta. 34 (5), 2013, 407-15.
PubMed
8) Schaap, AH. et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol. 97 (6), 2001, 954-60.
PubMed
9) Cartwright, RD. et al. Repeat Antenatal Betamethasone and Cardiometabolic Outcomes. Pediatrics. 142 (1), 2018, 10.1542/peds.2018-0522.
 
10) Doyle, LW. et al. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 10, 2017, 10.1002/14651858.CD001146.pub5.
 
11) Romagnoli, C. et al. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants : a 3-year follow-up. Pediatrics. 109 (6), 2002, e85.
PubMed
12) Doyle, LW. et al. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 10 (10), 2017, 1168-9.
 
13) Parikh, NA. et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants : effects on regional brain volumes. J Pediatr. 162 (4), 2013, 685-90.
PubMed
14) Dalziel, SR. et al. Antenatal exposure to betamethasone : psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ. 331 (7518), 2005, 665.
PubMed
15) Mori, R. et al. Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. J Pediatr. 159 (1), 2011, 110-4.
PubMed
16) Ishikawa, H. et al. The effects of antenatal corticosteroids on short- and long-term outcomes in small-for-gestational-age infants. Int J Med Sci. 12 (4), 2015, 295-300.
 
17) Baud, O. et al. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA. 317 (13), 2017, 1329-37.
PubMed
18) Baud, O. et al. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone : treatment effect according to gestational age at birth. Arch Dis Child Fetal Neonatal Ed. 104 (1), 2019, F30-F35.
PubMed
19) Doyle LW. et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants : a multicenter, international, randomized, controlled trial. Pediatrics. 117 (1), 2006, 75-83.
PubMed
20) Shah, SS. et al. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 10 (10), 2017, 10.1002/14651858.CD002057.pub4.
 
21) Shinwell, ES. Are inhaled steroids safe and effective for prevention or treatment of bronchopulmonary dysplasia? Acta Paediatr. 107 (4), 2018 554-6.
 
22) Bassler, D. et al. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. N Engl J Med. 378 (2), 2018, 148-57.
PubMed
23) Nakamura, T. et al. Early inhaled steroid use in extremely low birthweight infants : a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 101 (6), 2016, F552-6.
PubMed
24) Davis, EP. et al. Antenatal betamethasone treatment has a persisting influence on infant HPA axis regulation. J Perinatol. 26 (3), 2006, 147-53.
 
25) Alexander, N. et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab. 97 (10), 2012, 38-44.
 
26) Niwa, F. et al. The development of the hypothalamus-pituitary-adrenal axis during infancy may be affected by antenatal glucocorticoid therapy. J Neonatal Perinatal Med. 2019, 10.3233/NPM-180040. [Epub ahead of print]
 
27) Wolbeek, MT. Neonatal glucocorticoid treatment : long-term effects on the hypothalamus-pituitaryadrenalaxis, immune system, and problem behavior in 14-17 year old adolescents. Brain Behav Immun. 45, 2015, 128-38.
 
28) Haviv, HR. et al. The place of antenatal corticosteroids in late preterm and early term births. Semin Fetal Neonatal Med. 24 (1), 2019, 37-42.
PubMed
29) Kemp, MW. et al. The efficacy of antenatal steroid therapy is dependent on the duration of lowconcentration fetal exposure : evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 219 (3), 2018, 301. e1-16.
 
30) Schmitz, T. et al. Full versus half dose of antenatal betamethasone to prevent severe neonatal respiratory distress syndrome associated with preterm birth : study protocol for a randomised, multicenter, double blind, placebo-controlled, non-inferiority trial (BETADOSE). BMC Pregnancy Childbirth. 19 (1), 2019, 67.
 
31) Onland, W. et al. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 1 (1), 2017, 10.1002/14651858.CD010941.pub2.
 
P.270 掲載の参考文献
1) Weir, FJ. et al. Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. Acta Paediatr. 81 (9), 1992, 672-5.
PubMed
2) Holmstrom, H. et al. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr. 90 (2), 2001, 184-91.
PubMed
3) 坂野公彦ほか. 迅速キットを用いた血中B型ナトリウム利尿ペプチド (BNP) 値の経時的測定および極低出生体重児の未熟児動脈管開存症診断における有効性についての検討. 日本未熟児新生児学会雑誌. 20 (2), 2008, 233-40.
Medical*Online
4) Flynn, PA. et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr. 147 (1), 2005, 38-42.
PubMed
5) Sanjeev, S. et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol. 25 (11), 2005, 709-13.
PubMed
6) Farombi-Oghuvbu, I. et al. N-terminal pro-B-type natriuretic peptide : a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal. 93 (4), 2008, F257-60.
 
7) Nuntnarumit, P. et al. N-terminal-pro-brain natriuretic peptide : a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants. Acta Paediatr. 100 (9), 2011, 1217-21.
PubMed
8) Martinovici, D. Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment. Pediatr Cardiol. 32 (7), 2011, 953-7.
 
9) Toyoshima, K. et al. In vivo dilatation of the postnatal ductus arteriosus by atrial natriuretic peptide in the rat. Neonatology. 92, 2007, 139-44.
PubMed
10) 豊島勝昭. "BNPなどのバイオマーカーから何が分かる? ". 新生児循環管理なるほどQ&A. Neonatal Care春季増刊. 与田仁志編著. 大阪, メディカ出版, 2012, 153-8.
 
11) 豊島勝昭. 内分泌機能に大きく依存する新生児の循環調節 新生児内分泌調節と動脈管. 日本周産期新生児医学会雑誌. 49 (1), 2013, 168-71.
 
12) Morales, WJ. et al. Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor : a randomized study. Obstet Gynecol. 74 (4), 1989, 567-72.
PubMed
13) Eronen, M. et al. The effect of antenatal dexamethasone administration on the fetal and neonatal ductus arteriosus. A randomized double-blind study. Am J Dis Child. 147 (2), 1993, 187-92.
PubMed
14) Amorim, MM. et al. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol. 180 (5), 1999, 1283-8.
PubMed
15) Momma, K. et al. Increased constriction of the ductus arteriosus with combined administration of indomethacin and betamethasone in fetal rats. Pediatr Res. 25 (1), 1989, 69-75.
PubMed
16) Takami, T. et al. Increased Constriction of the Ductus Arteriosus by Dexamethasone, Indomethacin, and Rofecoxib in Fetal Rats. Circ J. 69 (3), 2005, 354-8.
PubMed
17) 未熟児動脈管開存症診療ガイドライン作成プロジェクトチーム (J-PreP). 根拠と総意に基づく未熟児動脈管開存症治療ガイドライン. 日本未熟児新生児学会雑誌. 22 (2), 2010, 255-67.
Medical*Online
18) Brion, LP. et al. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. Cochrane Database Syst Rev. 3, 2001, 10.1002/14651858.CD001148.
 
19) Toyoshima, K. et al. In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. Pediatric Res. 67 (2), 2010, 173-6.
PubMed
20) Lu, JF. et al. Magnesium sulfate in eclampsia and pre-eclampsia : pharmacokinetic principles. Clin Pharmacokinet. 38 (4), 2000, 305-14.
PubMed
21) del Moral, T. et al. Antenatal exposure to magnesium sulfate and the incidence of patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 27 (3), 2007, 154-7.
PubMed
22) Toyoshima, K. et al. Fetal reversed constrictive effect of indomethacin and postnatal delayed closure of the ductus arteriosus following administration of transplacental magnesium sulfate in rats. Neonatology. 96 (2), 2009, 125-31.
PubMed
23) Nakanishi, T. et al. Mechanisms of oxygen-induced contraction of ductus arteriosus isolated from the fetal rabbit. Circ Res. 72 (6), 1993, 1218-28.
PubMed
24) 吉田佳代ほか. ジアゾキシド投与を契機に晩期循環不全・動脈管再開通をきたした極低出生体重児の1例. 日本周産期新生児学会雑誌. 47 (3), 2011, 659-63.
 
25) 丸茂智恵子ほか. 高インスリン血性低血糖症に対しジアゾキシドを使用し, 動脈管開存症・心不全の管理に難渋した極低出生体重児の一例. 日本未熟児新生児学会雑誌. 24 (1), 2012, 143-7.
Medical*Online
26) Yoshida, K. et al. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology. 105 (3), 2014, 166-71.
PubMed
27) Toyoshima, K. Dilatation of the ductus arteriosus by diazoxide in fetal and neonatal rats. Pediatr Int. 59 (12), 2017, 1246-51.
PubMed
28) Sutherland, HW. et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Child. 49 (4), 1974, 283-91.
PubMed
29) Momma, K. et al. "Fetal and Neonatal Ductus Arteriosus Is Regulated with ATP-Sensitive Potassium Channel". Etiology and Morphogenesis of Congenital Heart Disease : From Gene Function and Cellular Interaction to Morphology [Internet]. Tokyo, Springer, 2016, 10.1007/978-4-431-54628-3_37.
 
30) Guarnieri, GF. Delayed closure of the ductus arteriosus in term newborns with congenital hypothyroidism : effect of L-thyroxine therapy. Pediatr Cardiol. 29 (1), 2008, 183-4.
PubMed
31) Carrascosa, A. et al. Thyroid function in 76 sick preterm infants 30-36 weeks : results from a longitudinal study. J Pediatr Endocrinol Metab. 21, 2008, 237-43.
PubMed
P.285 掲載の参考文献
1) Levick, JR. 血管の調節 I : 内因性調節. 心臓・循環の生理学. 岡田隆夫監. 東京. メディカル・サイエンス・インターナショナル. 2011, 233-48.
 
2) Levick, JR. 血管の調節 II : 神経とホルモンによる外因性調節. 249-68.
 
3) 日本循環器学会/日本心不全学会合同ガイドライン. "心不全の定義". 急性・慢性心不全診療ガイドライン (2017年改訂版). 2018, 10.
 
4) 岩永善高. "第3の神経体液性因子, バソプレシン系". 臨床心不全のいちばん大事なところ 60. 佐藤幸人編著. 大阪, メディカ出版, 2014, 60.
 
5) Artman, M. "Caridovascular Drug Therapy". Neonatal Cardiology. 2nd ed. New York, McGraw-Hill, 2011 231-50.
 
6) Ishiguro, A. et al. Effect of dopamine on peripheral perfusion in very-low-birth-weight infants during the transitional period. Pediatr Res. 72 (1), 2012, 86-9.
PubMed
7) Miyata, M. et al. Extensive use of vasodilator agents and functional echocardiography to monitor extremely-low-birth-weight infants in Japan. Journal of Neonatal-Perinatal Medicine. 9 (3), 2016, 261-9.
PubMed
8) Osborn, DA. et al. Randomised trial of dobutamine versus dopamine in preterm infants with low systemic blood flow. J Pediatr. 140 (2), 2002, 183-90.
 
9) Osborn, DA. et al. The effect of inotropes on morbidity and mortality in preterm infants with low systemic or organ blood flow. Cochrane Database Syst Rev. 24 (1), 2007, 10.1002/14651858.CD005090.pub2.
PubMed
10) Toyoshima, K. et al. Tailor-made circulatory management based on the stress-velocity relationship in preterm infants. J Formos Med Assoc. 112 (9), 2013, 510-17.
PubMed
11) 木村朋生. "代償性のレニン・アンジオテンシン・アルドステロン系の亢進が心不全を悪化させる". 57. 佐藤幸人編著. 大阪, メディカ出版, 2014, 60.
 
12) Shivanna, B. et al. Vasopressin and its analogues for the treatment of refractory hypotension in neonates. Cochrane Database Syst Rev. 3, 2013, 10.1002/14651858.CD009171.pub2.
 
13) Westerkind, A. et al. Clinical signs of heart failure are associated with increased levels of natriuretic peptide type B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr. 9 (3), 2004, 340-5.
PubMed
14) Michael, W. Role of type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 29 (6), 2006, 843-9.
 
15) 豊島勝昭. "BNPなどのバイオマーカーから何が分かる? ". 新生児循環管理なるほどQ&A. Neonatal Care春季増刊. 与田仁志編著. 大阪, メディカ出版, 2012, 153-8.
 
16) Levick, JR. "バイオマーカー ナトリウム利尿ペプチド". 2. 岡田隆夫監．東京. メディカル・サイエンス・インターナショナル．2011，http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf (2020年2月閲覧)
 
17) Levick, JR. "双胎間輸血症候群って何? どんな注意が必要? ". 2. 岡田隆夫監．東京. メディカル・サイエンス・インターナショナル．2011, 268-73.
 
18) 豊島勝昭ほか. 胎児心機能障害におけるナトリウム利尿ペプチドホルモンの臨床的意義. 日本小児循環器学会雑誌. 21 (2), 2005, 123-9.
Medical*Online
19) Mahieu-Caputo, D. et al. Pathogenesis of twin-twin transfusion syndrome : the renin-angiotensin system hypothesis. Fetal Diagn Ther. 16 (4), 2001, 241-4.
PubMed
20) Mahieu-Caputo, D. et al. Paradoxic activation of the renin-angiotensin system in twin-twin transfusion syndrome : an explanation for cardiovascular disturbances in the recipient. Pediatr Res. 58 (4), 2005, 685-8.
PubMed
21) 豊島勝昭ほか. 一絨毛膜性双胎の胎児・新生児循環の心臓血管内分泌学的検討. 周産期・新生児医学会雑誌. 43 (4), 2007, 999-1003.
Medical*Online
P.296 掲載の参考文献
1) Gravholt, CH. et al. Clinical practice guidelines for the care of girls and women with Turner syndrome : proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 77 (3), 2017, G1-G70.
 
2) Isojima, T. et al. New reference growth charts for Japanese girls with Turner syndrome. Pediatr Int. 51 (5), 2009, 709-14.
PubMed
3) 日本小児内分泌学会. ターナー症候群におけるエストロゲン補充療法ガイドライン. 日本小児科学会雑誌. 112 (6), 2008, 1048-50.
 
4) 日本小児科学会新生児委員会. 新生児に関する用語についての勧告. 日本小児科学会雑誌. 98 (10), 1994, 1946-50.
 
5) 日本小児内分泌学会・日本未熟児新生児学会. SGA性低身長症におけるGH治療のガイドライン. 日本小児科学会雑誌. 111 (4), 2007, 641-6.
 
6) Itabashi, K. et al. Longitudinal follow-up of height up to five years of age in infants born preterm small for gestational age ; comparison to full-term small for gestational age infants. Early Hum Dev. 83 (5), 2007, 327-33.
PubMed
7) Karlberg, J. et al. Growth in full-term small-for-gestational-age infants : from birth to final height. Pediatr Res. 38, 1995, 733-9.
PubMed
8) 日本小児内分泌学会ほか. SGA性低身長症におけるGH治療の実施上の注意 (2010.10.4再改訂). 日本小児科学会雑誌. 111 (4), 2007, 641-6. http://jspe.umin.jp/medical/gui.html (2019年11月閲覧)
 
9) Verkauskiene, R. et al. Puberty in children born small for gestational age. Horm Res Paediatr. 80, 2013, 69-77.
PubMed
10) Lem, AJ. et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog : results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 97 (11), 2012, 4096-105.
 
11) Deal, CL. et al. Growth Hormone Research Society workshop summary : consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 98 (6), 2013, E1072-87.
PubMed
12) Noonan, JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 116 (4), 1968, 373-80.
PubMed
13) Tohoku University School of Medicine. the RAS/MAPK syndromes homepage. http://www.medgen.med.tohoku.ac.jp/RasMapk%20syndromes.html (2019年11月閲覧)
 
14) 日本小児内分泌学会ほか. ヌーナン症候群における低身長に対するGH治療の実施上の注意. http://jspe.umin.jp/medical/gui.html (2019年11月閲覧)
 
15) 日本小児内分泌学会軟骨無形成症診療ガイドライン作成委員会. 軟骨無形成症診療ガイドライン. https://jspe.umin.jp/medical/gui.html (2019年11月閲覧)
 
16) Harada, D. et al. Final adult height in long-term growth hormone-treated achondroplasia patients. Eur J Pediatr. 176 (7), 2017, 873-9.
PubMed
17) Savarirayan, R. et al. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 381 (1), 2019, 25-35.
PubMed
18) Haffner, D. et al. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol. 9 (10), 1998, 899-907.
 
19) Seikaly, MG. et al. Use of rhGH in children with chronic kidney disease : lessons from NAPRTCS. Pediatr Nephrol. 22 (8), 2007, 1195-204.
PubMed
P.310 掲載の参考文献
1) Karlberg, J. A biologically-oriented mathematical model (ICP) for human growth. Acta Paediatr Scand Suppl. 350, 1989, 70-94.
PubMed
2) Tse, WY. et al. The infancy-childhood-puberty model of growth : clinical aspects. Acta Paediatr Scand Suppl. 356, 1989, 38-43 (discussion 44-35).
 
3) 日本小児内分泌学会・日本成長学会合同標準値委員会. 日本人小児の体格の評価に関する基本的な考え方. 2011. http://jspe.umin.jp/medical/taikaku.html (2019年11月閲覧)
 
4) Ogata, T. et al. Target height and target range for Japanese children : revisited. Clin Pediatr Endocrinol. 16 (4), 2007, 85-7.
PubMed
5) Marshall, WA. et al. Variations in pattern of pubertal changes in girls. Arch Dis Child. 44 (235), 1969, 291-303.
PubMed
6) Marshall, WA. et al. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 45 (239), 1970, 13-23.
PubMed
7) 板橋家頭夫ほか. 新しい在胎期間別出生時体格標準値の導入について. 日本小児科学会雑誌. 114 (8), 2010, 1271.
 
8) Sakurai, M. et al. Extrauterine growth restriction in preterm infants of gestational age < or = 32 weeks. Pediatr Int. 50 (1), 2008, 70-5.
PubMed
9) 小児内分泌学 改訂第2版. 日本小児内分泌学会編. 東京, 診断と治療社, 2016, 547-68.
 
10) Kato, N. et al. The Cubic Functions for Spline Smoothed L, S and M Values for BMI Reference Data of Japanese Children. Clin Pediatr Endocrinol. 20 (2), 2011, 47-9.
 
11) Tanaka, H. et al. Growth of Japanese breastfed infants compared to national references and World Health Organization growth standards. Acta Paediatr. 102 (7), 2013, 739-43.
PubMed
12) 日本母乳哺育学会. 母乳育児の成長曲線. http://square.umin.ac.jp/bonyuu/ (2019年11月閲覧)
 
13) Binder, G. et al. Rational approach to the diagnosis of severe growth hormone deficiency in the newborn. J Clin Endocrinol Metab. 95 (5), 2010, 2219-26.
 
14) Vigone, MC. et al. Mild Hypothyroidism in Childhood : Who, When, and How Should Be Treated? J Endocr Soc. 2 (9), 2018, 1024-39.
PubMed
15) Sperling, AM. Pediatric Endocrinology. 4th ed. Philadelphia, Elsevier, 2014.
 
16) van Tijn, DA. et al. Role of the thyrotropin-releasing hormone stimulation test in diagnosis of congenital central hypothyroidism in infants. J Clin Endocrinol Metab. 93 (2), 2008, 410-19.
PubMed
17) van der Burgt, I. Noonan syndrome. Orphanet J Rare Dis. 2 (4), 2007.
PubMed
18) World Health Organization. Physical status : the use of and interpretation of anthropometry. Report of a WHO expert committee. Geneva, World Health Organization, 1995, 854.
 
19) Itabashi, K. et al. New Japanese neonatal anthropometric charts for gestational age at birth. Pediatr Int. 56 (5), 2014, 702-8.
PubMed
20) 田中敏章ほか. SGA性低身長症におけるGH治療のガイドライン. 日本小児科学会雑誌. 111 (4), 2007, 641.
 
21) Goyal, D. et al. Epigenetic responses and the developmental origins of health and disease. J Endocrinol. 242 (1), 2019, T105-19.
 

書評

最近チェックした商品履歴

Loading...